Why Is Option Care Health (OPCH) Stock Down -27% Today?
Key Takeaways
- OPCH shares are plunging approximately 27% in premarket trading on April 30, 2026, from a prior session close of $26.87 to roughly $19.62
- The primary catalyst is a significant revenue miss in Q1 2026, with net revenue of $1.35 billion coming in well below the Wall Street consensus estimate of approximately $1.40 billion
- Management also cut the full-year 2026 revenue guidance sharply, reducing the range from the prior $5.8 billion–$6.0 billion to a revised $5.675 billion–$5.775 billion
- Adjusted EBITDA fell 6.3% year-over-year to $104.8 million, reflecting mounting cost pressures and an accelerating drag from Stelara biosimilar conversions
- The revenue guidance reduction at the midpoint represents a cut of roughly $175 million, signaling that headwinds from drug pricing and biosimilar substitution are more severe than previously disclosed
- Traders are watching the 8:30 a.m. ET earnings call for detail on the magnitude and duration of the Stelara impact and any updated commentary on the organic growth outlook
Opening Summary
Option Care Health, Inc. (OPCH) is one of the largest independent providers of home and alternate-site infusion therapy services in the United States, delivering intravenous medications and related nursing support to patients with chronic and acute conditions outside of traditional hospital settings. Shares are collapsing approximately 27% in premarket trading on April 30, 2026, sliding from the prior session's closing price of $26.87 to roughly $19.62 after the company reported Q1 2026 financial results before the market open. The earnings-driven selloff reflects both a meaningful revenue shortfall versus expectations and a significant reduction to the company's full-year guidance, driven by a far more severe-than-anticipated drag from Stelara biosimilar conversions.
Q1 2026 Earnings: Revenue Miss Triggers Severe Reaction
OPCH reported Q1 2026 net revenue of $1,350.7 million, a 1.3% year-over-year increase but sharply below the FactSet consensus estimate of approximately $1.40 billion — a miss of roughly $50 million, or about 3.5%. Adjusted diluted EPS came in at $0.40, flat year-over-year and roughly in line with estimates, offering little comfort. The deeper concern lies in profitability: Adjusted EBITDA declined 6.3% to $104.8 million, while GAAP net income fell 3.0% to $45.3 million. Operating cash flow was negative at -$12.1 million for the quarter, adding further pressure to investor confidence heading into the rest of the year.
Guidance Cut: The Core Catalyst Behind the Plunge
The more damaging element of the Q1 2026 release was the substantial revision to full-year guidance. OPCH lowered its 2026 net revenue outlook to $5.675 billion–$5.775 billion, down from the prior $5.8 billion–$6.0 billion range affirmed as recently as February. The midpoint of the new range sits at $5.725 billion, roughly $175 million below the midpoint of the previous guidance. Full-year Adjusted EBITDA guidance was also narrowed to $480 million–$505 million — maintaining the range but implying limited upside expansion given Q1 underperformance. The full-year Adjusted diluted EPS range of $1.82–$1.92 was also reaffirmed, though investors viewed the revenue cut as the overriding signal.
Stelara Biosimilar Headwind: Worse Than Expected
A central factor weighing on OPCH throughout 2025 and now accelerating in 2026 is the rapid adoption of biosimilar versions of Stelara (ustekinumab), a high-value biologic used to treat chronic inflammatory conditions. As patients transition from the branded reference product to lower-cost biosimilars, OPCH collects lower reimbursement per patient, directly compressing both revenue and gross profit. The company had previously estimated an annual revenue headwind of approximately $65 million–$70 million from this transition. The Q1 results and guidance cut suggest the pace of biosimilar conversion has accelerated meaningfully beyond those earlier projections, explaining why the guidance reduction exceeds what analysts had modeled. Management's language around "decisive actions to reaccelerate growth" underscores the severity of the challenge.
Market Context and Trading Activity
OPCH entered the session in a technically weakened position, already trading near its 52-week lows and roughly 25% below the analyst consensus price target of approximately $37.00. The stock had lost more than 3% on April 29 alone, suggesting some positioning ahead of the print. The premarket volume surge accompanying the 27% decline is well above any historical average, consistent with an institutional-driven flush following a dual shock of a revenue miss and a guidance cut. The broader healthcare services sector and home infusion peers will also be watched for sympathy moves. Health and specialty infusion ETFs may come under associated pressure as investors reassess reimbursement risk across the category. The broader market, while facing its own macro cross-currents from trade and rate policy, is not driving this move — OPCH's decline is company-specific and earnings-driven.
Trending AI Robots
For traders looking to navigate sharp, earnings-driven dislocations like today's move in OPCH, Tickeron's Trending AI Robots page provides a curated view of the platform's highest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots spanning thousands of tickers, strategies, and timeframes — but only the strongest performers are featured in the Trending section. Bots differ across key dimensions including trading style (momentum, mean reversion, swing), holding period, performance metrics, and the specific symbols they trade. Whether a trader is responding to a gap-down like today's or positioning for a longer-term recovery, the Trending AI Robots section helps cut through the noise and identify bots with a demonstrated edge in live market conditions. Traders seeking a data-driven approach to volatile environments are encouraged to explore the full offering.
What Comes Next for OPCH
The immediate focus will be on OPCH's 8:30 a.m. ET earnings call on April 30, 2026, where management is expected to provide detailed commentary on the pace of Stelara biosimilar adoption, the trajectory of chronic therapy volumes, and how the company plans to reaccelerate organic growth in the back half of the year. Investors will scrutinize whether the revised guidance range has adequately captured the remaining Stelara headwind or whether further cuts remain possible. Analysts who had been broadly bullish — with a consensus Moderate Buy and an average price target of approximately $37.00 — will likely revisit their models materially. Key upcoming data points include Q2 2026 results (expected in late July), any updates on M&A or capital allocation, and broader developments in specialty pharmacy reimbursement policy. Macro risks, including potential Medicaid or Medicare reimbursement changes under current legislative discussions in Washington, represent an additional variable that could weigh on the stock's recovery timeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for OPCH shows an upward move is likely
OPCH's Aroon Indicator triggered a bullish signal on June 25, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 231 similar instances where the Aroon Indicator showed a similar pattern. In of the 231 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 15, 2026. You may want to consider a long position or call options on OPCH as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where OPCH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OPCH broke above its upper Bollinger Band on May 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.476) is normal, around the industry mean (224.384). P/E Ratio (16.641) is within average values for comparable stocks, (120.761). Projected Growth (PEG Ratio) (1.197) is also within normal values, averaging (2.438). OPCH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.606) is also within normal values, averaging (2.531).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OPCH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement
Advertisement